REGISTER
Chinese Scientists Unveil Breakthrough in Early Alzheimer’s Detection with Blood Test Accuracy Surpassing 95%

A landmark study led by Prof. Yu Jintai’s team at Fudan University’s Huashan Hospital has announced a revolutionary blood test for early Alzheimer’s disease (AD) detection, achieving 95.6% accuracy in identifying preclinical stages of the disease. Published in Nature Medicine, the breakthrough integrates plasma biomarkers, AI-driven analytics, and longitudinal clinical data, offering hope for timely intervention in the world’s fastest-growing neurodegenerative disorder.



Figure 1. Group Photo of Jiafumin Team, United Team of Zhongshan Hospital and Mr. Lin


The Technology: Multi-Biomarker Panel and AI Modeling

The test combines levels of three key plasma biomarkers—p-tau181, p-tau217, and GFAP—with a machine learning model trained on data from 10,000+ participants across three continents (China, U.S., Europe). Prospective validation in the ADNI-4 cohort showed:


  • 95.6% accuracy in distinguishing preclinical AD from cognitively normal individuals.

  • 89.2% specificity and 92.1% sensitivity in identifying mild cognitive impairment (MCI) due to AD, outperforming traditional CSF biomarkers in accessibility and cost.


“For the first time, we can detect AD-related brain changes 15–20 years before symptoms appear,” said Prof. Yu, director of the National Clinical Research Center for Neurological Diseases. “This shifts the focus from treatment to prevention.”



Clinical Implications and Global Impact

  • Early Intervention: The test enables enrollment in prevention trials for at-risk individuals, such as Eli Lilly’s donanemab phase 4 study targeting preclinical AD.

  • Cost-Effectiveness: Priced at ¥800–1,200 ($110–170), the blood test is 5–10 times cheaper than PET imaging and accessible in standard hospitals.

  • Policy Impact: China’s National Health Commission plans to pilot AD screening programs in 30 cities by 2026, leveraging the test to monitor



Challenges and Future Directions

  • False Positives: The test’s accuracy drops to 88% in individuals with vascular dementia, necessitating follow-up MRI/CT scans.

  • Therapeutic Gap: While early detection is validated, no disease-modifying therapies (DMTs) exist for preclinical AD. The team is collaborating with Roche and Biogen on phase 2 trials of anti-tau monoclonal antibodies.

  • Global Rollout: The test will be available in U.S. clinics via LabCorp starting Q3 2025, with CE marking expected by year-end.




Expert Commentary

“This is a game-changer for global AD research,” said Dr. Maria Carrillo, Chief Science Officer at the Alzheimer’s Association. “By democratizing access to early diagnosis, we can finally address the ‘missing middle’—individuals at risk but not yet symptomatic.”


Dr. Reisa Sperling of Harvard Medical School added, “The combination of Chinese clinical data and AI innovation highlights how global collaboration accelerates breakthroughs. This test could halve AD’s economic burden by enabling timely lifestyle and pharmacological interventions.”

China’s Role in Redefining Neurodegenerative Care

With 15 million AD patients (projected to hit 40 million by 2050), China’s investment in AI-driven diagnostics—including a $1.2 billion national brain science initiative—positions it as a leader in neurodegenerative disease solutions. The Huashan team’s previous work on plasma p-tau217 was cited in the 2023 FDA approval of Cerenivus’ tau PET tracer, underscoring its influence on global standards.


As the world grapples with an aging population, this breakthrough offers a roadmap for transforming Alzheimer’s from an untreatable scourge into a manageable condition—provided therapeutic advancements keep pace with diagnostic innovation.


0
0
Loading